


## Dosing Options

**XHANCE**<sup>®</sup>  
(fluticasone propionate) nasal spray 93 mcg

XHANCE is administered in **each nostril twice daily**.



The recommended dosage is  
**1 spray per nostril\* twice daily.**

\*Equal to 186 mcg



=



30 days of treatment at  
this dosage requires  
**1 unit of XHANCE**

XHANCE is also approved for  
**2 sprays per nostril† twice daily.**


†Equal to 372 mcg



=



30 days of treatment  
at this dosage requires  
**2 units of XHANCE**



Maximum total daily dosage should not exceed 2 sprays in each nostril twice daily (8 sprays total).



**XHANCE is fragrance and alcohol free.**

Please see Indication and Important Safety Information on reverse.

Learn more at [www.XHANCEhcp.com](http://www.XHANCEhcp.com).



**INDICATION AND USAGE:** XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

### **IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS:** Hypersensitivity to any ingredient in XHANCE.

#### **WARNINGS AND PRECAUTIONS:**

- Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, *Candida albicans* infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma.
- Close monitoring for glaucoma and cataracts is warranted.
- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
- Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
- Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
- Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care.

**ADVERSE REACTIONS:** The most common adverse reactions (incidence  $\geq$  3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

**DRUG INTERACTIONS:** Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

**USE IN SPECIFIC POPULATIONS:** Hepatic impairment. Monitor patients for signs of increased drug exposure.

**Please see full Prescribing Information, including Instructions for Use, in pocket.**